The FDA approved a new type of blood test to detect colon cancer in adults aged 45 or older with an average risk of developing this disease.
Biotechnology company Guardant Health explained in a statement that the blood test, known as ‘Shield,’ was approved for individuals aged 45 or older with an average risk of colon cancer.
While the blood test does not replace colonoscopies, it could lead to more patients undergoing screening, as it requires less time and effort.
This is the first blood test approved by the FDA as a primary screening option for colorectal cancer, meaning healthcare providers in the U.S., including the public health insurance program for adults known as Medicare, can now offer the test.
The American Cancer Society estimates that over 150,000 people will be diagnosed with this type of cancer in 2024, and the disease will be responsible for more than 53,000 deaths in the country.
More than three out of every four people who die from this disease are not up to date with their screenings.
When colon cancer is detected at an early stage before it has spread, the five-year relative survival rate is 91%.
However, in the U.S., the screening rate is only around 59%, which is well below the National Colorectal Cancer Roundtable’s target of 80% for eligible individuals.
More than one in three eligible Americans (over 50 million people) do not undergo colorectal cancer screening, often due to the perception that other available options, such as colonoscopy or stool tests, are invasive, unpleasant, or uncomfortable, according to a report cited by California-based Guardant Health.
“With higher screening rates and early cancer detection, many more lives can be saved.”
A clinical trial published in The New England Journal of Medicine last March found that ‘Shield’ has an 83% effectiveness rate in identifying colorectal cancer, but it only detected 13% of the disease in its early stages.
What Is This New Type of Test?
Recently, the U.S. Food and Drug Administration (FDA) approved a new blood test designed to detect colon cancer in its early stages.
This test represents a significant advancement in the early detection of this disease, as it is less invasive than traditional methods like colonoscopy.
How Does It Work?
This blood test detects small amounts of tumor DNA that may circulate in the blood. By identifying these biomarkers, the test can indicate the presence of colon cancer or precancerous polyps.
What Are the Advantages of This Test?
Less Invasive: Unlike a colonoscopy, the blood test is a simple procedure and does not require special preparation.
Early Detection: It can detect cancer in its early stages, when it is more treatable.
Greater Convenience: It avoids the inconveniences associated with colonoscopy, such as bowel preparation and sedation.
Who Should Take This Test?
Although this test is a promising tool, it is important to consult with a doctor to determine if it is right for you. Factors to consider include:
Age: The test may be recommended for individuals starting at a certain age, depending on individual risk factors.
Family History: If you have a family history of colon cancer, you may be advised to take this test at a younger age.
Other Risk Factors: Other factors, such as inflammatory bowel disease, may influence the decision to take the test.
What Are the Limitations of This Test?
Does Not Replace Colonoscopy: While the blood test is a useful tool, it does not completely replace colonoscopy. In some cases, a colonoscopy may be necessary to confirm the diagnosis or remove polyps.
Not Perfect: No test is 100% accurate. False positives or false negatives are possible.
What Does This Mean for the Future?
The approval of this new blood test marks an important milestone in the fight against colon cancer. It is expected that this test, along with other innovations, will help increase early detection rates and improve outcomes for patients.
Want to Know More?
If you have any additional questions about this new test or about colon cancer screening in general, I recommend consulting with your doctor. You can also find information on reliable websites like the American Cancer Society.
No information should replace consultation with a doctor or other healthcare professional who can advise you based on your specific situation. If you do not have health insurance and need to consult a healthcare specialist, you can visit the office of
Dr. Carlos Arguello in Port St. Lucie 772-337-3334
1803 SE Port St. Lucie Blvd.
